Steven Cohen Day One Biopharmaceuticals, Inc. Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$12.03 - $17.69 $5.66 Million - $8.32 Million	470,247 New	470,247 $6.48 Million
Q4 2023 Feb 14, 2024	SELL	$9.68 - $15.37 $4.42 Million - $7.02 Million	-456,560 Reduced 83.84%	88,000 $1.28 Million
Q3 2023 Nov 14, 2023	BUY	$11.22 - $14.86 $4.64 Million - $6.15 Million	413,560 Added 315.69%	544,560 $6.68 Million
Q2 2023 Aug 14, 2023	BUY	$11.74 - $14.47 $1.54 Million - $1.9 Million	131,000 New	131,000 $1.56 Million
Q1 2023 May 15, 2023	SELL	$12.75 - $23.41 $5.89 Million - $10.8 Million	-461,631 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$18.77 - $22.0 $8.66 Million - $10.2 Million	461,631 New	461,631 $9.93 Million

181

84.1M

148K

218K

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $898M
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.